Updates on Oncolytic Virus Immunotherapy for Cancers
The 2018 annual Cambridge Healthtech Institute’s International Immuno-Oncology Summit in Boston, MA convened late August, and academic and industry researchers were allowed to debate and discuss oncolytic virology during the virus immunotherapy portion of the conference. The breakthrough agent, TVEC...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-03-01
|
| Series: | Molecular Therapy: Oncolytics |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770519300087 |
| _version_ | 1828747594834116608 |
|---|---|
| author | Cole Peters Paola Grandi Fares Nigim |
| author_facet | Cole Peters Paola Grandi Fares Nigim |
| author_sort | Cole Peters |
| collection | DOAJ |
| description | The 2018 annual Cambridge Healthtech Institute’s International Immuno-Oncology Summit in Boston, MA convened late August, and academic and industry researchers were allowed to debate and discuss oncolytic virology during the virus immunotherapy portion of the conference. The breakthrough agent, TVEC/IMLYGIC, as well as most other oncolytic viruses (OVs) in clinical trials, are demonstrating an immense synergy with T cell checkpoint inhibitors. To this extent, the marriage of T cell checkpoint inhibitors and OV is now vastly accepted, indicating the next phase in OVs is the recruitment of the immune system, and tailoring the immune response toward tumor clearance is a far better strategy than directly lysing the tumor outright with virus. The next field-shaping question for OVs is how to convert a patient’s immune response against their tumor. The talks this year focused on whether OVs can cause the emergence of a strong anti-tumor immunity intrinsically or whether vectors, which educate the immune system to detect tumor antigens, were more efficacious. Speakers presented novel transgenes to arm OVs and systems biology approaches to discover the best viral backbones to engineer into vectors. Here we summarize the meeting’s keynote talks, thematic principles running through the summit, and current developments in the OV field. |
| first_indexed | 2024-04-14T04:44:17Z |
| format | Article |
| id | doaj.art-23e6514568f840bdb86b31938581e935 |
| institution | Directory Open Access Journal |
| issn | 2372-7705 |
| language | English |
| last_indexed | 2024-04-14T04:44:17Z |
| publishDate | 2019-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncolytics |
| spelling | doaj.art-23e6514568f840bdb86b31938581e9352022-12-22T02:11:30ZengElsevierMolecular Therapy: Oncolytics2372-77052019-03-0112259262Updates on Oncolytic Virus Immunotherapy for CancersCole Peters0Paola Grandi1Fares Nigim2Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USAUniversity of Pittsburgh, Pittsburgh, PA 15213, USABrain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Corresponding author: Fares Nigim, MD, Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.The 2018 annual Cambridge Healthtech Institute’s International Immuno-Oncology Summit in Boston, MA convened late August, and academic and industry researchers were allowed to debate and discuss oncolytic virology during the virus immunotherapy portion of the conference. The breakthrough agent, TVEC/IMLYGIC, as well as most other oncolytic viruses (OVs) in clinical trials, are demonstrating an immense synergy with T cell checkpoint inhibitors. To this extent, the marriage of T cell checkpoint inhibitors and OV is now vastly accepted, indicating the next phase in OVs is the recruitment of the immune system, and tailoring the immune response toward tumor clearance is a far better strategy than directly lysing the tumor outright with virus. The next field-shaping question for OVs is how to convert a patient’s immune response against their tumor. The talks this year focused on whether OVs can cause the emergence of a strong anti-tumor immunity intrinsically or whether vectors, which educate the immune system to detect tumor antigens, were more efficacious. Speakers presented novel transgenes to arm OVs and systems biology approaches to discover the best viral backbones to engineer into vectors. Here we summarize the meeting’s keynote talks, thematic principles running through the summit, and current developments in the OV field.http://www.sciencedirect.com/science/article/pii/S2372770519300087 |
| spellingShingle | Cole Peters Paola Grandi Fares Nigim Updates on Oncolytic Virus Immunotherapy for Cancers Molecular Therapy: Oncolytics |
| title | Updates on Oncolytic Virus Immunotherapy for Cancers |
| title_full | Updates on Oncolytic Virus Immunotherapy for Cancers |
| title_fullStr | Updates on Oncolytic Virus Immunotherapy for Cancers |
| title_full_unstemmed | Updates on Oncolytic Virus Immunotherapy for Cancers |
| title_short | Updates on Oncolytic Virus Immunotherapy for Cancers |
| title_sort | updates on oncolytic virus immunotherapy for cancers |
| url | http://www.sciencedirect.com/science/article/pii/S2372770519300087 |
| work_keys_str_mv | AT colepeters updatesononcolyticvirusimmunotherapyforcancers AT paolagrandi updatesononcolyticvirusimmunotherapyforcancers AT faresnigim updatesononcolyticvirusimmunotherapyforcancers |